Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MADRIGAL PHARMACEUTICALS, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $300,000,000 (effective 2024-05-07).
- Action
- entry
- Agreement
- atm program
- Counterparty
- TD Securities (USA) LLC
- Value
- up to $300,000,000
- Effective
- 2024-05-07
Exact text from the filing
On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC, (“TD Cowen”), pursuant to which the Company may issue and sell through or to TD Cowen, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time having an aggregate sales price of up to $300,000,000 (the “ATM Offering”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
MADRIGAL PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2024-05-07).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC
- Effective
- 2024-05-07
Exact text from the filing
The Sales Agreement replaces and supersedes the prior sales agreement, dated June 1, 2021 and amended on May 9, 2023, between the Company and Cowen and Company, LLC, an affiliate of TD Cowen (the “Prior Sales Agreement”), which was terminated effective upon the entry into the Sales Agreement.
View on SEC.gov